Probably Genetic
Probably Genetic offers a solution for undiagnosed individuals suffering from rare diseases to quickly obtain answers to their symptoms. It is estimated that there are more than 400 million people globally with rare diseases, surpassing the combined number of cancer and HIV patients. Among these individuals, half remain undiagnosed, with children comprising a significant portion. Typically, it takes an average of 5-7 years for these patients to receive a diagnosis, but our system can provide answers within weeks. Our advanced Symptom Checker, available online, utilizes cutting-edge machine learning models to identify rare disease patients. They are then offered testing through our direct-to-consumer genetic testing service, enabling them to access potentially life-saving treatments and connect with advocacy communities. Additionally, we collaborate with pharmaceutical developers to offer sponsored testing programs, ensuring that patients can undergo genetic testing at minimal or no cost.
Probably Genetic offers a solution for undiagnosed individuals suffering from rare diseases to quickly obtain answers to their symptoms. It is estimated that there are more than 400 million people globally with rare diseases, surpassing the combined number of cancer and HIV patients. Among these individuals, half remain undiagnosed, with children comprising a significant portion. Typically, it takes an average of 5-7 years for these patients to receive a diagnosis, but our system can provide answers within weeks. Our advanced Symptom Checker, available online, utilizes cutting-edge machine learning models to identify rare disease patients. They are then offered testing through our direct-to-consumer genetic testing service, enabling them to access potentially life-saving treatments and connect with advocacy communities. Additionally, we collaborate with pharmaceutical developers to offer sponsored testing programs, ensuring that patients can undergo genetic testing at minimal or no cost.
Probably Genetic has raised $10.7M across 1 round. Its most recent round was a Series Unknown of $10.7M in Nov 2023. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Probably Genetic is featured in
Similar companies
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of sustainable and food alternatives.
NanoStruct is a biotechnology company that develops nanostructured sensor chips to identify bacteria and pathogens in food.
Tacalyx, a company originating from Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany, is dedicated to researching Tumor-Associated Carbohydrate Antigens (TACAs) as a potential new target for cancer therapy. TACAs are expressed specifically in tumors due to abnormal glycosylation, and contribute to processes like metastasis, angiogenesis, and immune suppression. Tacalyx utilizes advanced carbohydrate synthesis technology to create pure TACA structures, which are then used to develop antibodies for innovative cancer treatments.
Primogene is a biotechnology company that provides ingredient development, bioprocess manufacturing, and scalable production.
Mbiomics is a company in the field of biotechnology.
At EVANIUM, we make plant compounds like polyphenols and flavonoids more effective by improving their solubility, stability, and absorption. Our OPTISOLV® Technology helps deliver natural actives into food, nutraceuticals, pharmaceuticals, and personal care products — more effectively and efficiently. Our goal is to support brands in creating their next product innovation. Developed in Germany. Produced in Europe.
Picea Biosolutions is a biotechnology firm. Based on their core platform technology, they develop tailored expression systems for enzymes from picoliter to large-scale fermentation. They are building on their experience in engineering a wide range of industrial organisms including bacteria, yeast, and filamentous fungi. Their customized enzyme solutions are applicable across industries such as circular economy, food, and feed. Picea Biosolutions is headquartered in Offenburg, Baden-Wurttemberg and was founded in 2022.
KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity. The company's mission is to provide cancer patients with not only safe but also inexpensive immunotherapy, as well as to produce immunostimulatory drugs capable of preventing infectious illnesses.
iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.